Meeting
2023 ASCO Annual Meeting
Pharmacological cardioprotective strategy for non-metastatic patients affected by breast cancer receiving an anthracycline-based chemotherapy: Final results of the phase 3 SAFE trial.
Authors
Lorenzo Livi
Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy
Lorenzo Livi , Giuseppe Barletta , Francesca Martella , Calogero Saieva , Carlotta Becherini , Carlotta Bacci , Maria Riccarda Del Bene , Mario Airoldi , Domenico Amoroso , Luigi Coltelli , Giuseppe Pilato , Luca Visani , Viola Salvestrini , Fulvia Pedani , Marco Bernini , Lorenzo Orzalesi , Jacopo Nori , Simonetta Bianchi , Iacopo Olivotto , Icro Meattini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Clinical Trial Registration Number
NCT2236806
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 12079)
DOI
10.1200/JCO.2023.41.16_suppl.12079
Abstract #
12079
Poster Bd #
447
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Cardiac toxicity prevention in non-metastatic breast cancer patients treated with anthracycline-based chemotherapy: A randomized, placebo controlled, phase III trial—SAFE trial.
First Author: Icro Meattini
Poster
2023 ASCO Annual Meeting
Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial.
First Author: Takahiro Kogawa
Poster
2022 ASCO Annual Meeting
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin versus placebo in hormone receptor–positive early-stage breast cancer (CCTG MA32).
First Author: Dawn L. Hershman
Poster
2021 ASCO Annual Meeting
A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer.
First Author: Snehal Patel